The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.
PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.
PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.
Momentum stocks are only affected by a significant rise or fall of the VIX, unlike minimum volatility stocks, which are affected by even a minor change in the VIX.
